BOSTON, Massachusetts, USA – June 9, 2026
Novanta Inc. has announced a definitive agreement to acquire Riverpoint Medical in a transaction valued at up to $1.45 billion, significantly expanding its presence in the fast-growing minimally invasive surgery market and accelerating its strategy to build a more durable, recurring revenue business. Under the terms of the agreement, Novanta will acquire all outstanding equity interests of Riverpoint Medical for $1.2 billion in upfront cash consideration, along with a $250 million milestone payment expected in early 2027. The acquisition strengthens Novanta’s medical technology portfolio by adding a category-leading developer and manufacturer of advanced surgical consumables, implants, sutures, and specialized surgical instruments used across sports medicine, trauma, and cardiovascular surgery. Company leaders believe the transaction will immediately enhance revenue growth, profitability, cash flow generation, and long-term shareholder value while creating one of the industry’s most comprehensive OEM-focused surgical technology platforms.
Riverpoint Medical Expands Novanta’s Surgical Technology Portfolio
Riverpoint Medical has established itself as a leading innovator in minimally invasive surgical consumables and implantable technologies, serving major medical device manufacturers through private-label partnerships. Its portfolio includes advanced surgical fibers, suture anchors, implantable materials, biomedical textiles, and specialized surgical instruments designed for high-growth healthcare markets. The company’s competitive advantage is built on proprietary material science expertise, novel coating technologies, and the ability to manage complex product development and regulatory processes for OEM customers.
By bringing Riverpoint into its portfolio, Novanta gains access to differentiated technologies that complement its existing strengths in advanced surgery, precision medicine, robotics, and medical manufacturing. The acquisition is expected to deepen relationships with shared customers while creating new cross-selling opportunities across an expanded product portfolio. Company executives noted that Riverpoint’s strong innovation capabilities and high-growth profile make it an ideal strategic fit within Novanta’s long-term vision for healthcare technology expansion.
Strategic Transaction Doubles Recurring Medical Consumables Revenue
Advertisement
A key driver behind the acquisition is Novanta’s objective to increase exposure to recurring revenue streams and reduce dependence on cyclical capital equipment markets. Upon completion of the transaction, the company expects to double its recurring medical consumables revenue to approximately $300 million annually, while increasing the contribution of healthcare-related business to roughly 60% of total company revenue. Riverpoint is currently growing at approximately twice the pace of Novanta and is projected to maintain an annual revenue growth rate of 12% to 15% over the long term. The acquisition also expands Novanta’s addressable market opportunity by approximately $2 billion, creating additional growth potential in high-value surgical applications.
Beyond revenue expansion, the company expects the transaction to strengthen its global manufacturing footprint, enhance supply chain resilience, and improve responsiveness to customer needs through strategically located FDA-registered production facilities. These operational advantages are expected to support long-term scalability and competitiveness in the evolving medical technology sector.
Significant Financial Benefits Expected Following Integration
Novanta expects the acquisition to be immediately accretive to key financial metrics, including revenue growth, adjusted earnings per share, operating cash flow, and profitability. Under Novanta ownership, Riverpoint is projected to generate approximately $80 million in adjusted EBITDA during 2027, including anticipated synergies. Management also identified more than $80 million in cumulative profit and cash flow synergies over the first five years following closing, reflecting opportunities for operational integration and commercial expansion.
The transaction will be financed through a combination of cash on hand, existing credit facilities, and a recently completed equity raise. Subject to regulatory approvals and customary closing conditions, the acquisition is expected to close during the third quarter of 2026. Industry analysts view the deal as a strategically important step for Novanta, strengthening its position in high-growth surgical markets while reinforcing its transformation into a healthcare-focused technology company with a greater emphasis on recurring revenue, innovation, and long-term value creation.
Source: Novanta, Riverpoint Medical press release
